METHODS: After obtaining IRB approval we identified 165 patients treated at our center for primary urethral cancer between 1956 and 2017. Treatment was categorized as monotherapy (surgery or radiation), dual therapy (surgery and radiation, surgery and chemotherapy, or chemotherapy and radiation) or triple therapy (surgery, radiation and chemotherapy). Rates of different treatments were plotted by year of treatment to evaluate changes in treatment pattern. Multivariable Cox regression models were created to evaluate the association between treatment type and outcome while adjusting for disease characteristics.
INTRODUCTION AND OBJECTIVES: While Squamous Call
Variant (SCV) is the most common subtype in mixed urothelial bladder cancer, the effect of neoadjuvant chemotherapy (NACT) has not been fully elucidated. We assessed histopathologic outcomes and recurrence rates in this group of patients in response to NACT.
METHODS: We reviewed the records of 105 patients with SCV in the TURBT specimen who ultimately underwent cystectomy between 2008 and 2018. They were divided into 2 groups: NACT (25 patients) and no-NACT (80 patients). Our primary outcome was pathologic stage at time of cystectomy. Secondary outcomes included lymph node density (LND), persistence of SCV in the cystectomy specimen, and recurrence rates.
RESULTS: The median (IQR) age of the NACT and no-NACT was 60 (53-63) and 70 (62-79), respectively (p[0.0045) . The NACT and no-NACT groups were comparable with respect to race (p[0.8124), sex (p[0.3290) , and smoking status (p[0.4369). The most common chemotherapy regimens used were GC in 16 (60%), MVAC in 7 (28%), and others in 2 (8%). The rate of downstaging to pT0 at cystectomy was 44% vs 7.5% for the NACT and no-NACT, respectively (p<0.0001) (Figure) . SCV was less common in both groups at time of cystectomy, however, the NACT group (44%) had a lower rate of persistence than the no-NACT group (65%) (p[0.0614). Overall, 28% of patients treated with NACT and 25.3% with no NACT had positive lymph nodes (p[0.7924). Mean lymph node density was lower in the NACT compared to the no-NACT group (9.6 vs 26.1%, p[0.0011). Finally, the NACT group had fewer recurrences than the no-NACT group (12 vs 41.3%, p[0.0074).
CONCLUSIONS: The effect of NACT in variant histology bladder cancer is incompletely understood. In patients with SCV, our data suggests compelling evidence favoring the use of NACT in regards to histopathologic outcomes and recurrence rates. Longer follow-up is needed to determine the true effect on recurrence patterns.
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MP38-03 PLASMACYTOID UROTHELIAL CARCINOMA: IMPLICATIONS FOR NEOADJUVANT CHEMOTHERAPY AND CLINICOPATHOLOGIC OUTCOMES
Kyle Ericson*, Lewis Thomas, University Heights, OH, Byron Lee, Cleveland, OH INTRODUCTION AND OBJECTIVES: In urothelial carcinoma, plasmacytoid histologic features represent a rare variant that is often locally advanced at cystectomy. Data on plasmacytoid urothelial carcinoma (PUC) is limited to small case series and the ideal treatment remains unknown. Our objective herein is to report on clinicopathologic outcomes of patients with PUC and examine the role of neoadjuvant chemotherapy (NAC) in this group.
METHODS: All cystectomies performed from 2011-2018 at our institution were reviewed. Patients with PUC features on cystectomy were compared to patients without PUC. Categorical variables were compared using chi-squared analysis and Fisher's exact test when sample size was limited. Overall survival was compared with log-rank analysis and Cox proportional hazards regression to control for age, Charlson comorbidity index (CCI), gender, pathologic stage (! pT3), soft tissue margins, and nodal status.
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